- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07277413
Studie IDE892 jako monoterapie a v kombinaci u MTAP-deletovaných pokročilých solidních nádorů
Multicentrická studie hodnotící bezpečnost, účinnost a farmakokinetiku přípravku IDE892 jako monoterapie a kombinované terapie u účastníků s MTAP-deletovanými pokročilými solidními tumory
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Přehled studie
Postavení
Podmínky
- Rakovina slinivky
- Adenokarcinom žaludku
- Mezoteliom
- Rakovina močového měchýře
- Peritoneální mezoteliom
- Adenokarcinom jícnu
- Karcinom žlučových cest
- Pleurální mezoteliom
- Nemalobuněčný karcinom plic NSCLC
- Gastroezofageální rakovina (GC)
- NSCLC adenokarcinom
- Auto skvamózní buňky. - Jícen
- Urotheliální karcinom (UC)
Intervence / Léčba
Detailní popis
The purpose of this study is to evaluate safety, efficacy, and PK of IDE892 as monotherapy and combination therapy in adult participants with MTAP-deleted tumors who have progressed after standard therapy and represent a high unmet need. In the current stage, the combination will be focused on IDE892 with IDE397, an oral inhibitor of methionine adenosyltransferase 2A (MAT2A), to fully exploit the vulnerabilities associated with methylthioadenosine (MTA) accumulation in MTAP-deleted tumors while maintaining a substantial therapeutic index. The mechanistic rationale for this study is discussed in the following sections.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: IDEAYA Clinical Trials
- Telefonní číslo: +1 855 433 2246
- E-mail: IDEAYAClinicalTrials@ideayabio.com
Studijní místa
-
-
Arizona
-
Goodyear, Arizona, Spojené státy, 85338
- Nábor
- City of Hope Cancer Center-Phoenix
-
Kontakt:
- Amit Kulkarni, MD
- Telefonní číslo: 612-624-9604
- E-mail: amkulkarni@coh.org
-
Phoenix, Arizona, Spojené státy, 85054
- Nábor
- Mayo Clinic Arizona
-
Kontakt:
- Mitesh J. Borad, M.D.
- Telefonní číslo: 855-776-0015
-
-
California
-
Duarte, California, Spojené státy, 91010
- Nábor
- City of Hope Cancer Center-Duarte
-
Kontakt:
- Abhishek Tripathi, M.D.
- Telefonní číslo: 626-218-9200
- E-mail: atripathi@coh.org
-
Santa Rosa, California, Spojené státy, 95403
- Nábor
- Providence Medical Foundation
-
Kontakt:
- Ian Anderson, MD
- Telefonní číslo: 707-521-3830
- E-mail: ian.anderson@providence.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20016
- Nábor
- Johns Hopkins Sibley Memorial Hospital
-
Kontakt:
- Solmaz Sahebjam, MD
- Telefonní číslo: 202-669-6500
- E-mail: ssahebj1@jh.edu
-
Kontakt:
- Mahlet Atnafu
- Telefonní číslo: 202-669-6500
- E-mail: SibleyOncResReferral@live.johnshopkins.edu
-
-
Florida
-
Coral Springs, Florida, Spojené státy, 33065
- Nábor
- BRCR Global-Coral Springs
-
Kontakt:
- Alina Quintana
- Telefonní číslo: 561-447-0614
- E-mail: alinaq@brcrglobal.com
-
Jacksonville, Florida, Spojené státy, 32224
- Nábor
- Mayo Clinic Florida
-
Kontakt:
- Conor D. O'Donnell, M.B., B.Ch., B.A.O.
- Telefonní číslo: 855-776-0015
-
Orlando, Florida, Spojené státy, 32827
- Nábor
- Sarah Cannon Research Institute at Florida Cancer Specialists
-
Kontakt:
- Elizabeth Gilmore
- Telefonní číslo: 904-380-2410
- E-mail: Elizabeth.Griffith@Scri.com
-
Tampa, Florida, Spojené státy, 33612
- Nábor
- Moffitt Cancer Center
-
Kontakt:
- Mauricio Ribeiro, MD
- Telefonní číslo: 813-745-3242
- E-mail: mauricio.ribeiro@moffitt.org
-
Kontakt:
- Anisa Gonzalez
- Telefonní číslo: 813-745-3874
- E-mail: anisa.gonzalez@moffitt.org
-
-
Illinois
-
Zion, Illinois, Spojené státy, 60099
- Nábor
- City of Hope Cancer Center-Chicago
-
Kontakt:
- Evan Pisick, M.D.
- Telefonní číslo: 415-353-9674
- E-mail: episick@coh.org
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy, 55905
- Nábor
- Mayo Clinic Rochester
-
Kontakt:
- Kaushal Parikh, M.B.B.S.
- Telefonní číslo: 855-776-0015
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68130
- Nábor
- Nebraska Cancer Specialists
-
Kontakt:
- Lindsey Becker, Primary Study Coordinator
- Telefonní číslo: 402-691-5255
- E-mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
East Brunswick, New Jersey, Spojené státy, 08816
- Nábor
- START Astera, LLC
-
Kontakt:
- Hope Team Distribution List
- E-mail: hopeteam@startresearch.com
-
-
New York
-
New York, New York, Spojené státy, 10032
- Nábor
- Columbia University Irving Medical Center
-
Kontakt:
- Nurse Navigation Team: Contact for All Patient Referrals
- Telefonní číslo: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Nábor
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
-
Kontakt:
- E-mail: askphase1@jefferson.edu
-
Kontakt:
- askphase1@jefferson.edu
- Telefonní číslo: 215-586-0199
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37203
- Nábor
- Sarah Cannon Research Institute
-
Kontakt:
- Alydia Miller
- Telefonní číslo: 615-927-2212
- E-mail: alydia.miller@scri.com
-
Kontakt:
- Sarah Cannon Institute
- Telefonní číslo: 844-482-4812
- E-mail: asksarah@sarahcannon.com
-
-
Texas
-
Fort Worth, Texas, Spojené státy, 76104
- Nábor
- START Dallas Fort Worth
-
Kontakt:
- Kasie Newton
- Telefonní číslo: 682-350-3010
- E-mail: kasie.newton@startresearch.com
-
Houston, Texas, Spojené státy, 77030
- Nábor
- MD Anderson
-
Kontakt:
- Jordi Rodon Ahnert, MD, PhD
- Telefonní číslo: 713-563-1930
- E-mail: JRodon@mdanderson.org
-
Houston, Texas, Spojené státy, 77054
- Nábor
- NEXT Oncology Houston
-
Kontakt:
- Emma Morales
- Telefonní číslo: 832-384-7912
- E-mail: emorales@nextoncology.com
-
Irving, Texas, Spojené státy, 75039
- Nábor
- NEXT Oncology Dallas
-
Kontakt:
- Mofopefoluwa Akinwale
- Telefonní číslo: 972-893-8800
- E-mail: fakinwale@nextoncology.com
-
-
Utah
-
West Valley City, Utah, Spojené státy, 84119
- Nábor
- START Mountain Region, LLC
-
Kontakt:
- Marie Asay, Director, Nursing
- Telefonní číslo: 801-907-4770
- E-mail: marie.asay@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- Nábor
- NEXT Oncology Virginia
-
Kontakt:
- Maybelle De La Rosa
- Telefonní číslo: 703-783-4518
- E-mail: mdelarosa@nextoncology.com
-
-
Washington
-
Seattle, Washington, Spojené státy, 98104
- Nábor
- Swedish Cancer Institute
-
Kontakt:
- Siddhartha Devarakonda, MD
- Telefonní číslo: 206-386-2424
- E-mail: siddhartha.devarakonda@swedish.org
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.
- Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma [pleural or peritoneal], gastroesophageal cancers [squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC [adenocarcinoma, squamous cell carcinoma, and adeno-squamous] or UC [including mixed urothelial-squamous histology]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).
- Are willing and able to provide blood/tumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.
- Must be willing and able to provide the blood/serum/plasma samples
- Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)
- Have at least 1 measurable lesion according to RECIST version 1.1
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- Have life expectancy > 3 months
- Have adequate bone marrow and organ function
- Able to swallow and retain orally administered study drug/IMP.
- Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
- Male and female: willing to use contraception
Exclusion Criteria:
- Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids
- Have a known primary central nervous system (CNS) malignancy
- Have had other malignancies within 2 years prior to the first dose, with some exceptions
- Impaired cardiac function or clinically significant cardiac diseases
- Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter
- Have a history of severe infections within 4 weeks prior to the start of study treatment
- Hypertension (e.g., > 150/100 mmHg) that cannot be controlled by medications despite optimal medical therapy
- Other acute or chronic medical or psychiatric condition
- Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening
- Known or suspected viral hepatitis with a positive test at screening
- Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1
- Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks
- Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP
- Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein
- Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4/5, Strong inhibitors of P-gp and/or BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP
- Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study
- Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892
- Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and/or Protein arginine N-methyltransferase (PRMT) inhibitor
- Major surgery within 4 weeks before study entry
- Prior irradiation to > 25% of the bone marrow
- Known or suspected hypersensitivity to IDE892
Disease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)
- Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1/PD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.
- If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.
Eligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)
- Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors
- Must have progressed following at least 1 prior line of therapy
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Part 1: IDE892 Monotherapy Dose Escalation (MTAP-deleted advanced solid tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892. Dose levels will be escalated sequentially using a Bayesian Optimal Interval (BOIN) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK and pharmacodynamics (PD) and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
Experimentální: Part 2: IDE892 Monotherapy Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892. One or more dose levels at or below the maximum tolerated dose from Part 1 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
Experimentální: Part 3: IDE892 + IDE397 Combination Dose Escalation (MTAP-Deleted Solid Tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892 in combination with IDE397. Dose levels will be escalated using a modified toxicity probability interval (mTPI) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK, PD, and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
|
Experimentální: Part 4: IDE892 + IDE397 Combination Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892 in combination with IDE397. One or more dose levels at or below the maximum tolerated dose from Part 3 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)
Časové okno: 21 days following the first dose of IDE892 (each cycle is 21 days)
|
Incidence of DLTs of IDE892 will be determined in Parts 1 and 3 |
21 days following the first dose of IDE892 (each cycle is 21 days)
|
|
Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)
Časové okno: From first dose until 28 days after last dose (each cycle is 21 days)
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (graded based on Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) will be determined in Parts 1, 2, 3, and 4. |
From first dose until 28 days after last dose (each cycle is 21 days)
|
|
Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)
Časové okno: Approximately 2 years
|
Objective response rate (ORR: best objective response of complete response [CR] + partial response [PR]) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the Investigator |
Approximately 2 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall response rate (ORR) and duration of response (DOR) per RECIST version 1.1 (Parts 1 and 3)
Časové okno: Approximately 2 years
|
ORR and DOR per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Disease control rate (DCR) and duration of stable disease per RECIST version 1.1 (Parts 1, 2, 3, and 4)
Časové okno: Approximately 2 years
|
Disease control rate (disease control rate [DCR]: CR + PR + stable disease [SD]) and duration of SD per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Maximum Observed Plasma Concentration (Cmax) (Parts 1, 2, 3, and 4)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax is the highest observed plasma concentration of the study drug following administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Observed Concentration (Tmax)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Time to Maximum Observed Concentration (Tmax) after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUClast reflects total drug exposure from dosing until the last measurable concentration after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time of Last Quantifiable Concentration (Tlast)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Tlast is the time at which the final measurable drug concentration is observed after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUCinf represents total drug exposure extrapolated to infinite time after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Terminal Elimination Half-Life (t½)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
t½ is the time required for the plasma concentration of the drug to decrease by half during the terminal elimination phase after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Maximum Observed Plasma Concentration at Steady State (Cmax,ss)
Časové okno: Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax,ss is the maximum observed plasma concentration after achieving steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Concentration at Steady State (Tmax,ss)
Časové okno: Cycle 1 Day 15 (each cycle is 21 days)
|
Tmax,ss is the time from dosing to Cmax at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Trough Plasma Concentration at Steady State (Ctrough)
Časové okno: Cycle 1 Day 15 (each cycle is 21 days)
|
Ctrough is the concentration obtained immediately prior to the next scheduled dose at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau)
Časové okno: Cycle 1 Day 15 (each cycle is 21 days)
|
AUCtau represents drug exposure over one full dosing interval at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Clearance (CL/F)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
CL/F is the apparent clearance of the drug after extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Volume of Distribution (Vz/F)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Vz/F is the apparent volume of distribution following extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Accumulation Ratio (Rac)
Časové okno: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Rac is calculated as the ratio of AUC or Cmax at steady state compared with first dose, reflecting drug accumulation after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Edward Chan, MD, IDEAYA Biosciences
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění endokrinního systému
- Patologické procesy
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Mužská urogenitální onemocnění
- Urologická onemocnění
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Atributy nemoci
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Nemoci trávicího systému
- Gastrointestinální onemocnění
- Plicní onemocnění
- Novotvary endokrinních žláz
- Novotvary hlavy a krku
- Onemocnění slinivky břišní
- Novotvary, žlázové a epiteliální
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Neoplastické procesy
- Nemoci jícnu
- Novotvary plic
- Adenom
- Novotvary, mezoteliální
- Pleurální novotvary
- Urologické novotvary
- Karcinom
- Novotvary, dlaždicové buňky
- Onemocnění močového měchýře
- Karcinom, skvamózní buňky
- Novotvary jícnu
- Patologické stavy, příznaky a symptomy
- Spinocelulární karcinom jícnu
- Mezoteliom, maligní
- Opakování
- Mezoteliom
- Metastáza novotvaru
- Novotvary pankreatu
- Novotvary močového měchýře
- Karcinom, přechodná buňka
- Adenokarcinom jícnu
Další identifikační čísla studie
- IDE892-001
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .